– Unaudited 2024 total revenue of approximately $814 million, exceeding guidance –– Four approval applications submitted to FDA in 2024 –– Global launch preparations underway for sepiapterin for PKU, a $1 billion market opportunity; CHMP opinion expected Q2 2025, U.S. approval decision in July 2025 –  – License and collaboration agreement with Novartis for PTC518 program closed – – PIVOT-HD data readout for PTC518 expected Q2 2025 –WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: ...